Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CID-103 in Adults With Active and Chronic Active Renal Allograft Antibody Mediated Rejection
NCT07641426Phase 2Recruiting
- Sponsor
- CASI Pharmaceuticals, Inc.
- Start
- Jun 2026
- Primary completion
- May 2030
- Countries
- 1
01
Overview
A Phase 2 trial of CID-103 in antibody mediated rejection (AMR), sponsored by CASI Pharmaceuticals, Inc.. Started Jun 2026; status: recruiting.
02
Drugs
CID-103
03
Conditions
antibody mediated rejection (AMR)
Beyond the preview
Go deeper on NCT07641426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07641426.